Agilent Technologies has licensed BIA Separations' bio-monolithic
technology and intends to use it in the commercialisation of
analytical high performance liquid chromatography (HPLC)
Agilent Technologies is expanding its nucleic acid active
pharmaceutical ingredient (API) manufacturing facility in Boulder,
Colorado, US, as the industry gravitates towards the
development of oligonucleotide-based drugs.
Agilent Technologies has signed an agreement with Groton Biosystems
to co-market measuring solutions for the pharmaceutical industry,
as the Process Analytical Technology (PAT) initiative gains
popularity among drug manufacturers...
Agilent Technologies has introduced its new microarray that offers
high-resolution genomic coverage, whilst enabling multiple
experiments per slide. The technology has the potential to make
savings both in time and cost.
Agilent Technologies launches its latest microarray solution for
analysing activity at regulatory regions of genomes, enabling
researchers to examine gene regulation in a more efficient and
Agilent Technologies has launched what it says is the industry's
first gas chromatograph/mass spectrometer (GC/MS) system with a
user interface that allows the electronic sharing of application
A hive of activity at Agilent Technologies has trnsformed the
company into a significant player in the competitive microarray
platform market with the expansion of its array-based genomics,
disease research and drug R&D applications.
Agilent Technologies has launched what it claims is the industry's
first fully automated, high-throughput 'lab-on-a-chip system' for
basic life science research and drug discovery. The Agilent 5100
Agilent Technologies has launched a software package to help drug
companies keep a close eye on the quality of chemical compounds.
The firm says the product is the first of its kind, allowing a more
than seven-fold increase in the...